HMPL-523 Food Effect and Proton Pump Inhibitor Study

NCT05571787 | Completed Phase 1 FDA Drug

• 1 other identifier: 2022-523-00US1
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers

Conditions

Relapsed or Refractory Lymphoma

Outcome Measures

Primary Outcomes (4)

• PK parameter for HMPL-523: AUC0-t

  Area under the concentration time curve from time 0 to the last measurable concentration

  Day 1 to Day 31

• PK parameter for HMPL-523: AUC0-inf

  Area under the concentration time curve from time 0 extrapolated to infinity

  Day 1 to Day 31

• PK parameter for HMPL-523: Cmax

  Maximum observed plasma concentration

  Day 1 to Day 31

• PK parameter for HMPL-523: tmax

  Time to reach the maximum observed plasma concentration

  Day 1 to Day 31

Secondary Outcomes (4)

• Assessment of safety procedures findings

  Day 1 to Day 31

• PK parameter for metabolite M1: AUC0-t

  Day 1 to Day 31

• PK parameter for metabolite M1: AUC0-inf

  Day 1 to Day 31

• PK parameter for metabolite M1: Cmax

  Day 1 to Day 31

Study Arms (4)

Treatment A

EXPERIMENTAL

Subjects in treatment A will fast overnight for at least 10 hours prior to HMPL-523 dosing.

Drug: HMPL-523

Treatment B

EXPERIMENTAL

Subjects in treatment B will receive a standardized high-fat meal approximately 30 minutes before HMPL-523 administration

Drug: HMPL-523

Treatment C

EXPERIMENTAL

Subjects in treatment C will receive a standardized low-fat meal approximately 30 minutes before HMPL-523 administration

Drug: HMPL-523

Treatment D

EXPERIMENTAL

Subjects in treatment D will receive rabeprazol 1 hour prior to receiving a standardized low-fat meal. On Day 26 subjects will also receive HMPL-523 approximately 30 minutes after the standardized low-fat breakfast

Drug: HMPL-523; Drug: Rabeprazole

Interventions

HMPL-523 DRUG

700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26

Treatment A; Treatment B; Treatment C; Treatment D

Rabeprazole DRUG

40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26

Treatment D

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• The volunteer is male or female between the ages of 18 and 55 years old (inclusive) at the time of informed consent.
• The volunteer has a body mass index (BMI)\>18 and ≤29.9 kg/m2at screening.
• Females must be postmenopausal (defined as absence of menses for at least 1year without alternative medical cause)or permanently sterile by total hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.
• Males, including those who have had a successful vasectomy, must use a condom during sexual intercourse with women of childbearing potential, starting from their first dose of study drug through 30 days after their last dose of study drug. Alternatively, abstinence is allowed if it is the normal and preferred lifestyle of the volunteer.
• The volunteer must provide written informed consent prior to any study specific screening procedures.
• The volunteer is willing and able to comply with all aspects of the protocol, as determined by the PI.

You may not qualify if:

• The volunteer has a known history of any gastrointestinal surgery or any condition possibly affecting drug absorption (eg, cholecystectomy, gastrectomy, achlorhydria, peptic ulcer disease, or history of stomach or intestinal surgery or resection). Note: Appendectomy and hernia repairs are allowed.
• The volunteer had a clinically significant illness within 8 weeks or a clinically significant infection within 4 weeks prior to the first dose.
• The volunteer has evidence of a clinically significant deviation from normal in the physical examination, vital signs, or clinical laboratory determinations at screening or at Day -1 check-in (baseline).
• The volunteer has systolic blood pressure \>140 mmHg oradiastolic blood pressure \>90mmHg.
• The volunteer has a clinically significant ECG abnormality, including a marked baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTcF interval \>480msec), or hasa family history of prolonged QTc syndrome or sudden death.
• The volunteer has a history of smoking or use of nicotine-containing substances within the previous 2 months, as determined by medical history or volunteer's verbal report and confirmed by cotinine test at check-in.
• The volunteer has a history of drug or alcohol misuse within 6 months prior to screening or a positive urine drug test at screening or at check-in.
• The volunteer has been diagnosed with acquired immune deficiency syndrome or has performed tests that are positive for human immunodeficiency virus (HIV), HepatitisBvirus (HBV), orHepatitis C virus (HCV).
• The volunteer has participated in a clinical trial of other study drug before screening, and the time since the last use of other study drug is less than 5 times the half-life or 4 weeks, whichever is longer, or the volunteer is currently enrolled in another clinical trial.1
• The volunteer has consumed grapefruit, starfruit, Seville oranges, or their products within 7 days prior to the first dose.
• The volunteer has consumed herbal preparations/medications, including, but not limited to, St. John's Wort, kava, ephedra (ma huang), Ginkgo biloba, dehydroepiandrosterone, yohimbe, saw palmetto, and ginseng, within 7 days prior to the first dose (21days for St.John's Wort).
• The volunteer has experienced a weight loss or gain of \>10% within 4 weeks prior to the first dose as noted by medical history and weight at screening and check-in.
• The volunteer has received blood or blood products within 4 weeks, donated blood or blood products within 8 weeks prior to the first dose or donated double red cell within 16weeks prior to first dose.
• The volunteer has used any over-the-counter (OTC) medications or prescription drugs (medications that can lower gastric acid in particular) within 2 weeks prior to the first dose.
• The volunteer is allergic to any of the study drugs (or its excipients) to be given in this study.

Sponsors & Collaborators

• Hutchmed: lead

Study Sites (1)

PPD Austin

Austin, Texas, 78744, United States

Location

MeSH Terms

Conditions

Recurrence; Lymphoma

Interventions

Rabeprazole

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Open-label, 4-Period, Randomized 6-Sequence Study

Study Record Dates

• First Submitted: October 5, 2022
• First Posted: October 7, 2022
• Study Start: July 13, 2022
• Primary Completion: September 22, 2022
• Study Completion: September 22, 2022
• Last Updated: February 23, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)